Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...

I had abandoned my transverse abdominis (TA or TVA). Unlike the rectus abdominis (those six-pack abs we typically think of in the core), the TA muscles support the spine and the way we hold our ...

In the latest quarter, 8 analysts provided ratings for Vertex VERX, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts ...

Vertex's total revenues for Q4 2024 were $178.5 million, marking a 15.2% increase year-over-year. How much did Vertex invest in research and development for 2025? Vertex plans to invest ...

The end of the Vertex-Verve collaboration comes as investors are reevaluating once sky-high expectations for the gene editing industry as commercial realities set in. Shares of Verve and top companies ...

Multiple pregnancies (9.2%), placenta previa with or without implantation (11.4%), severe pre-eclampsia (3.1%), severe ICP in pregnancy (3.1%), macrosomia in pregnancy (3.4%), malposition (breech, ...

Transverse aortic constriction (TAC) is a frequently used model to investigate pressure overload-induced progressive heart failure (HF); however, there is considerable phenotypic variation among ...